Vivek Subbiah, Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute, shared a post on X:
”An honor to deliver not one but two keynote lectures + join panel discussions at OncoNext meeting in São Paulo, Brazil. Energizing discussions on AI, precision oncology and clinical trials. Brazil is fast becoming a powerhouse for registrational clinical trials.
Grateful to Drs. Fabio Franke, Roberto Pestana, Juliana Beal and all the brilliant Brazilian oncologists for the QandA and warm hosting. And thanks to the Pfizer Inc., Pfizer Oncology Medical team for the momentum.”
Other Articles Featuring Vivek Subbiah on OncoDaily.
